Medical Condition News

RSS

FDA accepts Eisai's resubmission of perampanel NDA for review

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's resubmission of the New Drug Application (NDA) for perampanel (E2007), an investigational drug, for the treatment of partial-onset seizures associated with epilepsy.

5 Mar 2012

New depression treatment “safe and effective”

Stimulating the brain with a weak electrical current is a safe and effective treatment for depression and could have other surprise benefits for the body and mind, a major Australian study of transcranial Direct Current Stimulation (tDCS) has found.

5 Mar 2012

Asthma first aid charts launched

The National Asthma Council Australia has updated its popular First Aid for Asthma chart and launched a new paediatric Kids’ First Aid for Asthma chart, with advice reflecting the latest evidence and medications.

5 Mar 2012

High blood pressure due to stress maybe due to the immune system

If stress is giving you high blood pressure, blame the immune system. T cells, helpful for fighting infections, are also necessary for mice to show an increase in blood pressure after a period of psychological stress, scientists have found.

5 Mar 2012

Certain microRNAs key to controlling actions of BDNF, linked to brain cell survival

Studying tiny bits of genetic material that control protein formation in the brain, Johns Hopkins scientists say they have new clues to how memories are made and how drugs might someday be used to stop disruptions in the process that lead to mental illness and brain wasting diseases.

5 Mar 2012

Zalicus completes reformulated Z160 Phase 1 clinical trial for pain

Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the successful completion of a Phase 1 clinical trial evaluating the pharmacokinetics and safety of a new formulation of Z160, a novel oral N-type calcium channel blocker.

5 Mar 2012

Inhalation of nitric oxide could help improve blood flow to ischemic brain

LMU researchers developed a new strategy for the treatment of stroke, which could help to improve blood flow to ischemic brain. Strokes are due to a localized reduction in the blood supply to the brain, mainly due to the blockage of a vessel by a blood clot.

5 Mar 2012

Thrombotech receives FDA IND approval for THR-18 Phase IIa clinical trial in stroke victims

Hadasit Bio-Holdings a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced Thrombotech Ltd., a portfolio company which Hadasit holds a 24% stake in, received an IND approval from the Food and Drug Administration enabling the initiation of a Phase IIa clinical trial in the U.S.

5 Mar 2012

Nuvilex overcomes fundamental challenges faced in stem cell therapy

Nuvilex, Inc., an emerging biotechnology provider of cell and gene therapy solutions, released information today about the company's cell encapsulation technology and the breakthrough in stem cell research which overcomes specific fundamental challenges faced in stem cell therapy—host rejection and migration of implanted cells away from the target site.

5 Mar 2012

ETView completes Viva EB Endobronchial Blocker Technical File submission for review by MDC

ETView today announced that the company has successfully completed a Technical File submission for review by Medical Device Certification GmbH ("MDC"). The Technical File review initiates the Conformité Européenne, or "European Conformity" ("CE") registration process.

5 Mar 2012

Anthera continues Phase 2b PEARL-SC clinical study in SLE patients

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases including cardiovascular and autoimmune disorders, today announced the continuation of the Phase 2b PEARL-SC clinical study following an interim analysis of all safety and efficacy data.

5 Mar 2012

Concert commences dosing in CTP-499 Phase 2 clinical trial for diabetic nephropathy

Concert Pharmaceuticals, Inc. today announced the initiation of dosing in a Phase 2 clinical trial evaluating CTP-499, an investigational drug for the treatment of diabetic nephropathy, the leading cause of chronic kidney disease (CKD) in the US.

5 Mar 2012

Tips to assess when gambling could be leading to process addiction

Whether it's a March Madness office betting pool or sitting in the sports books in Las Vegas placing bets on the Masters Golf Tournament and opening week of Major League Baseball, the coming months are fraught with sporting events which lure millions of gamblers to place their bets.

5 Mar 2012

BioLineRx granted Israeli approval for BL-7040 Phase II clinical trial for IBD

BioLineRx a biopharmaceutical development company, announced today that it has received approval from the Israeli Ministry of Health for commencing a Phase II clinical trial of BL-7040, an orally available molecule for treating Inflammatory Bowel Disease (IBD).

5 Mar 2012

Researchers identify mechanism with which cancer cells protect themselves against damage

Although many cancer drugs have already been in use for decades, their mode of action is still unknown. The new research results now challenge a mechanism of action that was previously proposed for a group of drugs and supported with experiments: the Topoisomerase I-inhibitor Camptothecin (Top1 inhibitor for short) and its derivatives used in chemotherapy, Topotecan and Irinotecan.

5 Mar 2012

Concert, Fast Forward partner to advance new approach to treat spasticity and pain in MS

Concert Pharmaceuticals, Inc. and Fast Forward, LLC, the National Multiple Sclerosis Society's subsidiary devoted to bridging the gap between research and drug development, today announced a new collaboration to fund the preclinical advancement of C-21191, a deuterium-modified subtype-selective GABAA modulator developed by Concert with the therapeutic potential of treating spasticity and pain in multiple sclerosis (MS).

5 Mar 2012

FDA clears Covidien Solitaire FR revascularization device

Covidien, a leading global provider of healthcare products, today announced that the Solitaire FR revascularization device has been cleared by the U.S. Food and Drug Administration. The Solitaire FR device is intended to restore blood flow to the brain in patients suffering acute ischemic stroke by mechanically removing blood clots from blocked vessels.

5 Mar 2012

KYTHERA commences two ATX-101 Phase III trials for reduction of submental fat

KYTHERA Biopharmaceuticals, Inc., a privately-held biotechnology company focused on the development and commercialization of prescription products in aesthetic medicine, today announced the initiation of two pivotal U.S. Phase III trials of ATX-101, a first-in-class injectable drug under clinical investigation for the reduction of submental (under the chin) fat.

5 Mar 2012

Special computer algorithms can help doctors to make rapid diagnoses of known diseases

Just like urine and blood, breath contains traces of the products of metabolism. Such products can also be signs of infection, inflammation or cancer. For their analysis, computational bioinformatics researchers at the Cluster of Excellence "Multimodal Computing and Interaction" at Saarland University developed special computer algorithms that can help doctors to make diagnoses quickly and reliably.

5 Mar 2012

Inovio's SynCon vaccine for HPV types 6 and 11 induces CD8+ T cells in mice

Inovio Pharmaceuticals, Inc. announced today that its SynCon therapeutic vaccine for human papillomavirus (HPV) types 6 and 11, which are associated with head & neck cancers and genital warts, among other conditions, induced strong antigen-specific CD8+ T cells in mice.

5 Mar 2012